Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 2/20 | 0.36 |
| ▸ | PLK1 | P53350 | 3/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.32 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.32 |
| ▸ | ADA | P00813 | 5/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6133662 | 0.88 | ADA (0.34) | PLK1PTGER1ADA | |
| SCHEMBL6133722 | 0.84 | ACLY (0.52) | ACLYPTGER1ADA | |
| SCHEMBL6133372 | 0.81 | ADA (0.54) | PLK1MRGPRX4PTGER1ADA | |
| SCHEMBL6133844 | 0.79 | ADA (0.38) | ACLYADA | |
| Hydrochloric Acid SCHEMBL6134584 | 0.76 | SLC1A5 (0.42) | ACLYPLK1PTGER1ADA | |
| SCHEMBL6134058 | 0.76 | FFAR1 (0.37) | ACLYPTGER1 | |
| SCHEMBL6133239 | 0.75 | ADA (0.47) | ADA | |
| Hydrochloric Acid SCHEMBL6134055 | 0.75 | ADA (0.35) | PLK1ADA | |
| Hydrochloric Acid SCHEMBL6133359 | 0.74 | ADA (0.37) | ACLYPTGER1ADA | |
| SCHEMBL6133659 | 0.74 | ACLY (0.41) | ACLYPTGER1ADA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908940-B2 | Imidazole compounds and their use as adenosine deaminase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-21 | — | — | US | claimed |
| US-20040097571-A1 | Imidazole compounds and their use as adenosine deaminase inhibitors | ASTELLAS PHARMA INC. (JP) | 2004-05-20 | — | — | US | claimed |
| US-6908940-B2 | Imidazole compounds and their use as adenosine deaminase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-21 | — | — | US | disclosed |
| US-20040097571-A1 | Imidazole compounds and their use as adenosine deaminase inhibitors | ASTELLAS PHARMA INC. (JP) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097571-A1 | Imidazole compounds and their use as adenosine deaminase inhibitors | ADA, AMPD2, AMPD1 | ACLY 1604/4885PLK1 4417/4885MRGPRX4 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.